Compare Charles River Laboratories Intl. Inc (CRL) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Jabil Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $304.45 (market cap $14.23B), while Jabil Inc trades at $298.65 (market cap $31.35B). The key difference: Jabil Inc is far larger — about 2.2× Charles River Laboratories Intl. Inc's market cap, and Jabil Inc pays a 0.11% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Jabil Inc for 23 Days on average.
| CRL | JBL | |
|---|---|---|
Market Cap | $14.23B | $31.35B |
Volume | 1,176,885 | 1,337,978 |
Sector | Health | Technology |
52-Week High | $310.77 | $385.50 |
52-Week Low | $149.93 | $192.49 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $17.06B | $33.63B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
JBL trades at $299.47, down 3.14% amid bearish technical signals despite strong Q4 2026 earnings that beat estimates with EPS of $4.40 versus $4.07 expected. The stock shows neutral oscillators but bearish moving averages, with support at $296 and resistance at $303. Revenue grew to $29.80B in 2025 with net income of $657M, while 2026 projections indicate $36.0B revenue and $1.0B net income, supported by AI infrastructure demand.
Outlook remains positive with 60.87% analyst buy ratings and a $434.75 consensus price target implying 45% upside. Key risks include high debt levels and market volatility, but strong earnings momentum and AI-driven growth in fiscal 2027 provide investment opportunity. Monitor execution against guidance and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
